Zydus Cadila gets US FDA marketing nod for 3 drugs (PharmaBiz)
Zydus Cadila has received three product approvals from the US FDA in quick succession. The group has received approvals to market benzonatate tablets 100 and 200 mg, naproxen tablets and tentative approval for amlodipine besylate tablets 2.5, 5 and 10 mg.

Cadila Healthcare Gets US FDA Approvals For Three Products (Nasdaq)
(RTTNews) - Tuesday, Cadila Healthcare announced that the company is in receipt of three US FDA approvals for marketing Benzonatate tablets in the strength of 100mg and 200mg, Naproxen tablets and tentative approval for Amlodipine Besylate tablets 2.5mg, 5mg, and 10 mg.